Special children's drug development included in the examination and approval
Mooncake,Red Bean Mooncake,Jelly Mooncake,Snow Skin Mooncake ZHONGSHAN G.H.L. TRADING CO., LTD. , https://www.ghltrade.com Recently, the words “accelerating the establishment of a scientific and rational food and drug safety system†in the government work report have aroused public concern. However, in the area of ​​drug safety, the use of drugs by children has also aroused heated discussions among members.
Liu Yinglong, a member of the National Committee of the Chinese People's Political Consultative Conference and director of the Beijing Children's Cardiovascular Diagnosis and Treatment Center, said that the problem of children's drug use is very prominent. Sun Fengyuan, a member of the National Committee of the Chinese People's Political Consultative Conference and the First Central Hospital of Tianjin, feels the same. He specifically submitted a proposal to solve the problem of drug use for children. . It is understood that at present, the main problems faced by children in China's drug use include: lack of children's special dosage forms, lack of children's medication instructions or information in the drug product manuals, and weak research and development of children's special drugs.
Jiao Hong, a member of the National Committee of the Chinese People's Political Consultative Conference and deputy director of the State Food and Drug Administration, said that in the next phase, the State Food and Drug Administration will adopt a series of measures to encourage children's drug research and development: On the one hand, encourage enterprises to develop suitable for children of different ages. Formulations and specifications of medicines. Encourage the declaration of children's dosage forms and specifications when applying for innovative drugs. At the same time, innovative drugs for children's special diseases and rare diseases will be incorporated into special approval procedures. On the other hand, we will improve the relevant systems for children's drug administration, improve children's clinical drug use regulations, and encourage companies to actively improve information on children's drug use.